Products & Innovation / Scientific Resources

The evidence behind the platform.

Cerenome is built on evidence, and this is where it lives. Explore the research, congress presentations, and scientific materials behind our diagnostics, therapeutics, and data. Written for the clinicians and researchers who want to go deep.

Browse the evidence.

Filter by what you treat, what you’re researching, or how you like to read.

Enrolling Trials

How far our programs have come.

The evidence looks different depending on where a program sits, CNSide® is already validated and reimbursed in the real world; REYOBIQ™ is generating trial data across three of the hardest CNS diagnoses; and the platform’s data layer is proving out what happens when the two are studied together.

CNSide®

Validation studies, guideline recognition, coverage, and health economics and outcomes research (HEOR): the evidence behind a test already in clinical use. Deeper product and clinical detail lives at cnside-dx.com.

REYOBIQ™ / ReSPECT™

Phase 1 data spanning recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer, the earliest published look at an investigational program still in active trials. Visit respect-trials.com for more details.

Platform & data

Real-world evidence and integration research examining what changes when diagnostics and therapeutics data are studied as one connected system.

Now part of the diagnostic standard.

The updated NCCN CNS Cancers Guidelines now include CSF circulating tumor cell analysis alongside tumor-derived DNA, expanding the leptomeningeal metastases diagnostic standard beyond CSF cytology, so ordering CSF analysis like that of CNSide® now sits within guideline-supported practice.

From the field.

Clinicians and researchers on what changes when detection, treatment, and data work as one.